FGFR3 and Alzheimer disease: If, on the other hand, a minority of cases of AD are characterized by a deficiency of NE and an excess of the other four modulators, this would suggest a different pharmacological treatment strategy: boosting noradrenergic transmission (desipramine, nortriptyline, reboxetine, or atomoxetine) while suppressing transmission of the other modulators (e.g., with ACH blocking agents such as atropine, scopolamine, or mecamylamine).